Omega Funds closes $438M for its Fund VI to invest in life sciences startups

Omega Funds, a global life sciences-based investment firm that creates and invests in life sciences companies that target our world’s most urgent medical needs, has closed $438 million in capital commitments for its Omega Fund VI. With Fund VI, the firm will continue to execute on its strategy of creating and investing in life sciences companies that target the most urgent medical needs. In conjunction with the funding, Omega Funds also announced that industry veteran Bernard Davitian will be joining the firm as a Partner, beginning January 2020.

Founded in 2004 by Otello Stampacchia, Omega focuses on identifying and supporting companies through value inflection points across the full arc of innovation, from company formation through clinical milestones and commercial adoption. Omega Funds’ portfolio companies have brought 37 products to market in multiple therapeutic areas, including oncology, rare diseases, precision medicine and others.

Since its inception in 2004, Omega Funds has raised more than $1 billion to invest in exceptional entrepreneurs developing innovative products across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others.

Omega Funds has a strong track record of identifying and supporting great management teams and companies by providing domain knowledge and perspective, network connectivity, and capital. Omega Funds’ portfolio companies have brought 37 new products to market and the firm’s investments have contributed to 24 successful portfolio company IPOs and 35 portfolio company exits via M&A.

“We appreciate the trust from our limited partners and their support of our distinctive investment style, which is guided by our conviction in people, products and breakthrough ideas, not by conventional categories,” said Otello Stampacchia, Ph.D., Managing Director of Omega Funds. “Fund VI builds on our modus operandi aimed at investing in and, in many cases, actively combining innovative science with exceptional founders and company builders.”

Fund VI is stage-agnostic and is expected to be deployed across companies in the U.S. and Europe. Similar to past funds, Fund VI investments will include a variety of investment approaches, from company founding and creation to early venture rounds and late-stage public investing, as well as direct secondary transactions.

“We believe this is the most exciting time to be investing in life sciences in a generation, but it requires diverse skills to capture the opportunity set,” added Dr. Stampacchia. “At Omega, we have thoughtfully assembled a team that has the experience, insights and connections needed to successfully identify and harvest innovation from both sides of the Atlantic.”